162 related articles for article (PubMed ID: 14714685)
1. Competition policy in patent cases and antitrust.
Sobel G
Adv Genet; 2003; 50():23-64; discussion 507-10. PubMed ID: 14714685
[TBL] [Abstract][Full Text] [Related]
2. An analysis of the evolution of the written description requirement vis-à-vis DNA and biotechnological inventions.
Greenbaum D
Recent Pat DNA Gene Seq; 2007; 1(2):138-44. PubMed ID: 19075928
[TBL] [Abstract][Full Text] [Related]
3. The Role of Regulatory Agencies and Intellectual Property: Part II.
Noonan KE
Cold Spring Harb Perspect Med; 2015 Mar; 5(7):a020834. PubMed ID: 25775920
[TBL] [Abstract][Full Text] [Related]
4. Strategies for strengthening patent protection of pharmaceutical inventions in light of federal court decisions.
Pillai X; Kinney WA
Curr Top Med Chem; 2010; 10(18):1929-36. PubMed ID: 20615184
[TBL] [Abstract][Full Text] [Related]
5. State action antitrust immunity for public hospitals: it depends on what you mean by "foreseeable".
Ward PC
J Health Law; 2000; 33(1):1-23. PubMed ID: 10788225
[TBL] [Abstract][Full Text] [Related]
6. Using the written description requirement to limit broad patent scope, allow competition, and encourage innovation in biotechnology.
Mull WC
Health Matrix Clevel; 2004; 14(2):393-435. PubMed ID: 15503695
[TBL] [Abstract][Full Text] [Related]
7. An analysis of federal circuit discrimination: the evolution of the written description requirement vis-a-vis DNA and biotechnological inventions concerns for synthetic biology.
Greenbaum D
Recent Pat DNA Gene Seq; 2011 Dec; 5(3):153-65. PubMed ID: 21787273
[TBL] [Abstract][Full Text] [Related]
8. Unsettling drug patent settlements: a framework for presumptive illegality.
Carrier MA
Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
[TBL] [Abstract][Full Text] [Related]
9. Antitrust issues in the settlement of pharmaceutical patent disputes, Part II.
Leary TB
J Health Law; 2001; 34(4):657-71. PubMed ID: 11833411
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Myriad on the Future Development and Commercialization of DNA-Based Therapies and Diagnostics.
Wales M; Cartier E
Cold Spring Harb Perspect Med; 2015 Sep; 5(12):. PubMed ID: 26337114
[TBL] [Abstract][Full Text] [Related]
11. Nonobviousness of pharmaceutical inventions: implications for patent prosecution and litigation.
Dhulap S; Kulkarni M
Pharm Pat Anal; 2019 Jul; 8(4):91-107. PubMed ID: 31414965
[TBL] [Abstract][Full Text] [Related]
12. Design-around biotechnology patents: an analysis of US Federal Circuit decisions shows the possibility of designing around biotechnology patents.
Wang SJ
Hum Vaccin; 2011 Jan; 7(1):125-8. PubMed ID: 21263222
[TBL] [Abstract][Full Text] [Related]
13. Law machines: scale models, forensic materiality and the making of modern patent law.
Pottage A
Soc Stud Sci; 2011 Oct; 41(5):621-43. PubMed ID: 22164718
[TBL] [Abstract][Full Text] [Related]
14. Prometheus: the Supreme Court redefines the patentability of diagnostic inventions.
Kumamoto A; Schmid CL
Recent Pat DNA Gene Seq; 2012 Dec; 6(3):193-6. PubMed ID: 22812581
[TBL] [Abstract][Full Text] [Related]
15. Patent first, ask questions later: morality and biotechnology in patent law.
Bagley MA
William Mary Law Rev; 2003 Dec; 45(2):469-547. PubMed ID: 15570677
[TBL] [Abstract][Full Text] [Related]
16. Harvard v. Canada: the myc mouse that still squeaks in the maze of biopatent law.
Deftos LJ
Acad Med; 2001 Jul; 76(7):684-92. PubMed ID: 11448821
[TBL] [Abstract][Full Text] [Related]
17. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
Levy MS
Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
[TBL] [Abstract][Full Text] [Related]
18. Patent prosecution strategies for biotechnological inventions.
Yeh JJ; Fernandez D
Assay Drug Dev Technol; 2004 Dec; 2(6):697-702. PubMed ID: 15674028
[TBL] [Abstract][Full Text] [Related]
19. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
Paine CS
Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
[No Abstract] [Full Text] [Related]
20. Pharmaceutical patent settlements: the antitrust risks.
Balto DA
Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
[No Abstract] [Full Text] [Related]
[Next] [New Search]
